Phases, active trials: Phase 1: 24, Phase 2: 17, Phase 3: 49, Other: 10
Amgen's pipeline is defined by three breakthrough areas: targeted oncology (KRAS G12C inhibition with Lumakras/sotorasib, BiTE bispecific T-cell engagers led by Blincyto), cardiometabolic (Repatha/evolocumab for LDL lowering, olpasiran for Lp(a)), and inflammation/rare disease (Tezspire/tezepelumab for severe asthma, Otezla/apremilast). The KRAS franchise represents Amgen's most watched competitive program. Lumakras is the first approved KRAS inhibitor, and Amgen's pipeline of next-generation KRAS G12C inhibitors and KRAS combinations is closely tracked by the oncology community. Their BiTE platform (multiple CD19, BCMA, and other targets) continues generating new programs in hematology.
- Oncology (KRAS G12C, BiTE T-cell engagers)
- Cardiometabolic (PCSK9, Lp(a), HCM)
- Inflammation (TSLP, IL-5)
- Rare bone disease (denosumab)
- Hematology (BiTE, lymphoma)
- Lumakras (sotorasib): KRAS G12C inhibitor, NSCLC/CRC
- Blincyto (blinatumomab): CD19xCD3 BiTE, ALL/NHL
- Repatha (evolocumab): PCSK9 inhibitor, cardiovascular
- Tezspire (tezepelumab): TSLP, severe asthma
- Olpasiran: siRNA, Lp(a) lowering
- AMG 193: MTAP-deletion solid tumors
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate… NCT07493512 | Primary completion moved at least 2 years 6 months later | Recruiting |
10 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's… NCT06245408 | Oct 22, 2026 · Estimated | Phase 3 |
6 more on the Completions page. See the calendar →
Monitor the Amgen pipeline daily
Get a daily digest when Amgen registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Obesity | 8 |
| Overweight | 5 |
| Extensive Stage Small Cell Lung Cancer | 4 |
| Small Cell Lung Cancer | 4 |
| Cardiovascular Disease | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Neuromyelitis Optica Spectrum Disorder | 3 |
| Prostate Cancer | 3 |
Amgen's KRAS combination trials are the most watched oncology programs for anyone developing drugs in KRAS-altered cancers (particularly NSCLC, CRC, and pancreatic cancer). New Lumakras combination registrations signal competitive threat to programs developing SOS1, SHP2, or other KRAS-pathway inhibitors.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Amgen's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Amgen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Amgen pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1… NCT07575399 | Recruiting | Trial sites expanded: 45 → 53 locations | 2026-10-09 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing… NCT06745323 | Active, Not Recruiting | Completion pushed from May 10, 2029 to Aug 10, 2029 | 2026-10-07 |
| Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the… NCT07811999 | Recruiting | Recruitment opened | 2026-10-06 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell… NCT07134088 | Active, Not Recruiting | Completion pushed from Jun 18, 2030 to Sep 16, 2032 | 2026-10-06 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and… NCT06987539 | Recruiting | Trial sites expanded: 9 → 13 locations | 2026-10-06 |
Each trial page shows every change DataLookout has recorded for that trial.